Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | See Remarks | June 01, 2025 | June 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date June 01, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,000 |
Reported balance
After 2025-06-01 transaction · row 1
1 source rowRow 1 · 2025-06-01 · Grant · Acquired 55,000 · Balance 55,000 F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2: Each RSU was granted on June 1, 2025 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2035-06-01 | Direct | 315,000 |
Reported balance
After 2025-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-01 · Grant · Acquired 315,000 · Balance 315,000 F3: 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
F2: Each RSU was granted on June 1, 2025 for no consideration.
F3: 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 125,204 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2035-02-21 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 10,575 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.30 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 9,333 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.75 · Expires 2032-01-11 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 16,752 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.50 · Expires 2033-03-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 12,350 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.65 · Expires 2031-03-04 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 5,333 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.15 · Expires 2030-03-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 3,056 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.30 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 5,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-05-21 · Disposition to issuer · Disposed 5,775 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.10 · Expires 2027-01-30 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-05-21 · Disposition to issuer · Disposed 9,626 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2021 Filed Jun 17, 2021 18:39 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 576 | $3.73 | $2,148.48 |
DisclosureSEC source: 0001494650-21-000078 · wf-form4_162396951566080.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,590 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 18:11 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 2,304 | $3.92 | $9,031.68 |
DisclosureSEC source: 0001494650-21-000040 · wf-form4_161601902357190.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,166 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 17:20 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $3.51 Strike: $3.51 | $280,800.00 |
DisclosureSEC source: 0001494650-21-000021 · wf-form4_161524198877881.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-04 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 4, 2021. Twenty-five percent (25%) of the option vests and becomes exercisable on March 4, 2022, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 17:20 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 53,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-21-000021 · wf-form4_161524198877881.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,903 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2022, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 14:53 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $4.25 | $4,250.00 |
DisclosureSEC source: 0001494650-20-000113 · wf-form4_159967758159267.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,570 Read SEC document |
| September 01, 2020 Filed Sep 9, 2020 14:53 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $4.30 | $4,300.00 |
DisclosureSEC source: 0001494650-20-000113 · wf-form4_159967758159267.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,570 Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 14:00 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $5.03 | $5,030.00 |
DisclosureSEC source: 0001494650-20-000111 · wf-form4_159837843383113.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,570 Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 14:00 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $5.25 | $5,250.00 |
DisclosureSEC source: 0001494650-20-000111 · wf-form4_159837843383113.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,570 Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 500 | $5.10 | $2,550.00 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 5 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,003 Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $5.15 | $5,150.00 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 4 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,503 Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $5.26 | $5,260.00 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 3 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,503 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 567 | $5.01 | $2,840.67 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 6 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,570 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 2,000 | $5.13 | $10,260.00 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,503 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 18:49 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 1,000 | $5.10 | $5,100.00 |
DisclosureSEC source: 0001494650-20-000109 · wf-form4_159779092449842.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,503 F1 · balance_after: Includes 346 shares acquired under the Company's employee stock purchase plan on June 30, 2020 at a per share purchase price of $7.34. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 07:05 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantRestricted Stock Units · Derivative | 0 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001494650-20-000029 · wf-form4_158375190577729.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,567 Underlying: Common Stock · 0 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 07:05 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 45,850 | $5.41 Strike: $5.41 | $248,048.50 |
DisclosureSEC source: 0001494650-20-000029 · wf-form4_158375190577729.xml · derivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,850 Underlying: Common Stock · 45,850 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 17, 2021 18:06 UTC Amendment | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 45,850 | $5.41 Strike: $5.41 | $248,048.50 |
DisclosureSEC source: 0001494650-21-000036 · wf-form4a_161601875045296.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,850 Underlying: Common Stock · 45,850 shares Expires 2030-03-06 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 17, 2021 18:06 UTC Amendment | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 30,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-21-000036 · wf-form4a_161601875045296.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,070 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| June 28, 2019 Filed Jul 9, 2019 07:30 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 4,032 | $5.64 | $22,740.48 |
DisclosureSEC source: 0001494650-19-000068 · wf-form4_156267181841385.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,157 F1 · kind: Shares acquired under the OptiNose, Inc. 2017 Employee Stock Purchase Plan on June 28, 2019 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2019 Filed Mar 6, 2019 18:28 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001494650-19-000029 · wf-form4_155191490404525.xml · derivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2029-02-28 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 28, 2019. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2020, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 29, 2018 Filed Jan 8, 2019 16:53 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,125 | $13.60 | $42,500.00 |
DisclosureSEC source: 0001494650-19-000009 · wf-form5_154698439827414.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: Shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on June 29, 2018 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:42 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 86,637 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062328 · a4.xml · derivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,637 Underlying: Common Stock · 86,637 shares Expires 2027-10-11 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on October 12, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.